Key result
A 22-year-old man with laryngeal synovial sarcoma treated with neoadjuvant chemotherapy, total laryngectomy, and adjuvant radiotherapy remained recurrence-free at 12 months of follow-up.
Why the study?
Laryngeal synovial sarcoma is exceptionally rare, and reporting such cases may improve future diagnosis, evaluation, and management of this entity.
Case Report (n=1)
Laryngeal synovial sarcoma is a rare malignancy that can present with hemoptysis and may be successfully managed with a multimodal approach including surgery, chemotherapy, and radiotherapy.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to rare laryngeal tumors in young adults with hoarseness; leaves open evidence-based management strategies.
Background: Synovial sarcoma is a mesenchymal malignancy that most commonly arises in the lower extremities. Fewer than 5% of cases originate in the head and neck, and laryngeal involvement is exceptionally rare. Case Presentation: A 22-year-old man presented with a 6-month history of progressive hoarseness and hemoptysis. Direct laryngoscopy was performed, and biopsies were obtained. Histopathological examination established the diagnosis of laryngeal synovial sarcoma. The patient received three cycles of neoadjuvant chemotherapy, followed by total laryngectomy with bilateral neck dissection. Adjuvant radiotherapy was initiated postoperatively, and the patient remained recurrence-free at 12 months of follow-up. Discussion: Fewer than 5% of synovial sarcomas occur in the head and neck, and laryngeal involvement is rare. Three histopathological subtypes are recognized: monophasic, biphasic, and poorly differentiated. Immunohistochemistry and detection of the t(X; 18) translocation play a key role in diagnosis. Surgical resection remains the mainstay of treatment, although chemoradiotherapy may also be beneficial. Recurrence is a major concern, with local recurrence reported in up to 45% of patients and distant metastasis in approximately 33%. Conclusion: Because laryngeal synovial sarcoma is rare, reporting such cases may improve future diagnosis, evaluation, and management of this uncommon entity.
No takes yet. Share an insight, caveat, or question.
Iravani et al. (2026) conducted a case report in Laryngeal Synovial Sarcoma (n=1). Neoadjuvant chemotherapy, total laryngectomy, and adjuvant radiotherapy was evaluated on Recurrence. A 22-year-old man with laryngeal synovial sarcoma treated with neoadjuvant chemotherapy, total laryngectomy, and adjuvant radiotherapy remained recurrence-free at 12 months of follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: